List of Excipients in Branded Drug DEFERASIROX ORAL

Generic Drugs Containing DEFERASIROX ORAL

Company	Ingredient	NDC	Excipient
Ascend Laboratories LLC	deferasirox oral	67877-675	CELLULOSE, MICROCRYSTALLINE
Ascend Laboratories LLC	deferasirox oral	67877-675	CROSPOVIDONE
Ascend Laboratories LLC	deferasirox oral	67877-675	HYDROGENATED CASTOR OIL
Ascend Laboratories LLC	deferasirox oral	67877-675	POLOXAMER 188
Ascend Laboratories LLC	deferasirox oral	67877-675	POVIDONE K30
Ascend Laboratories LLC	deferasirox oral	67877-675	SILICON DIOXIDE

What are the Most Frequently-Used Excipients in DEFERASIROX ORAL?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	CROSPOVIDONE
1	HYDROGENATED CASTOR OIL
1	POLOXAMER 188
1	POVIDONE K30
1	SILICON DIOXIDE

Deferasirox Oral Excipient Strategy, Patent Exposure, and Commercial Opportunities

Last updated: August 19, 2026

Deferasirox oral products are differentiated by formulation performance rather than by active-ingredient novelty. The main commercial opportunities are pediatric acceptability, lower administration burden, improved dispersion, lactose-free or surfactant-reduced formulations, and generic products that reproduce the exposure profile of Jadenu while avoiding the administration limitations of Exjade. Exjade is a dispersible tablet, while Jadenu is available as a film-coated tablet and granules. The products contain the same active ingredient but have different dose, bioavailability, administration, and excipient requirements.[1][2]

What oral deferasirox products are approved by the FDA?

The FDA has approved deferasirox for chronic iron overload caused by blood transfusions and for non-transfusion-dependent thalassemia syndromes in specified patients. The principal reference products are Exjade and Jadenu, both associated with Novartis.[1][2]

Product	Dosage form	FDA application	Initial approval	Key administration profile
Exjade	Tablets for oral suspension	NDA 021882	2005	Disperse in water or apple or orange juice before administration; take on an empty stomach
Jadenu	Film-coated tablets	NDA 207968	2015	Swallow whole; may be taken on an empty stomach or with a light meal
Jadenu Sprinkle	Granules	NDA 207968 supplement	2015-era product line	Sprinkle on soft food and administer immediately

Jadenu was developed as a more convenient formulation with higher systemic exposure than Exjade. The FDA label describes Jadenu as having approximately 30% greater bioavailability than Exjade tablets for oral suspension, which is reflected in lower recommended doses.[2]

How do Exjade and Jadenu differ technically?

Attribute	Exjade	Jadenu
Primary patient burden	Tablet must be dispersed before dosing	Tablet can be swallowed whole
Food instruction	Empty stomach	Empty stomach or light meal
Dose conversion	Higher milligram dose	Approximately 30% lower dose than Exjade
Pediatric utility	Useful when suspension is acceptable	Granules improve administration for patients unable to swallow tablets
Excipient challenge	Rapid wetting, dispersion, sedimentation, taste	Mechanical strength, dissolution, film coating, swallowability
Generic development	Demonstrate dispersible-tablet performance	Demonstrate film-coated-tablet or granule bioequivalence

What excipients are used in deferasirox oral formulations?

The reference formulations use conventional solid-dose excipients, but each component has a defined functional role. The most commercially important variables are wetting, dispersion, tablet disintegration, lubrication, coating, taste, and dose uniformity.

Exjade excipient system

The Exjade label identifies the following inactive ingredients:

• Lactose monohydrate
• Microcrystalline cellulose
• Crospovidone
• Povidone
• Sodium lauryl sulfate
• Colloidal silicon dioxide
• Magnesium stearate

This system is designed for a dispersible tablet rather than a conventional swallowable tablet. The formulation must break apart rapidly in liquid and maintain a sufficiently uniform dispersion during the short interval between preparation and administration.[1]

Excipient	Primary function in Exjade-type formulation
Lactose monohydrate	Diluent and compressibility aid
Microcrystalline cellulose	Filler and tablet-strength contributor
Crospovidone	Superdisintegrant
Povidone	Binder
Sodium lauryl sulfate	Wetting agent and dissolution aid
Colloidal silicon dioxide	Glidant and flow aid
Magnesium stearate	Lubricant

Sodium lauryl sulfate is particularly relevant because deferasirox has limited aqueous solubility. Removing or reducing the surfactant may impair wetting and dissolution, but high surfactant loading can create taste, gastrointestinal tolerability, and regulatory comparability concerns.

Jadenu tablet excipient system

Jadenu tablets use a related core excipient platform, with a film-coating system added for mechanical protection, identification, and swallowability. The labeled excipients include lactose monohydrate, microcrystalline cellulose, crospovidone, povidone, sodium lauryl sulfate, colloidal silicon dioxide, magnesium stearate, and coating materials including hypromellose, titanium dioxide, talc, and propylene glycol.[2]

The formulation opportunity is not simply to copy the Exjade platform. Jadenu requires a tablet with:

1. Adequate hardness for handling and packaging.
2. Rapid disintegration and dissolution after swallowing.
3. Consistent drug release across strengths.
4. Acceptable coating integrity.
5. Low tablet burden for chronic treatment.
6. Suitable dose proportionality or validated strength-specific performance.

Jadenu Sprinkle excipient considerations

Granules are designed for patients who cannot reliably swallow tablets. The granules must remain discrete during storage, distribute evenly over soft food, avoid unacceptable taste, and release deferasirox rapidly after administration.

Important technical parameters include:

• Granule size distribution
• Dust generation
• Surface adhesion to food
• Dose recovery from the food vehicle
• Moisture sensitivity
• Taste masking
• Stability after opening
• Uniformity across low and high strengths

Granules create a potential product differentiation route, but they also increase manufacturing and packaging complexity. A successful product must control segregation and dose loss during dispensing.

What excipient strategy is most attractive for new deferasirox products?

The strongest strategy is a formulation platform that targets administration barriers without materially changing deferasirox exposure.

Taste-masked pediatric granules

Taste is a major development issue because deferasirox is administered chronically and may be used in children. Taste masking can use:

• Polymer film coating
• Lipid or wax coating
• Ion-exchange resin complexes
• Functional pH-sensitive polymers
• Multiparticulate granules
• Flavor systems compatible with iron-overload patients

Taste masking must not delay drug release or materially alter bioavailability. Coatings that are too dense may reduce dissolution, while porous coatings may fail during administration over food.

Lactose-free formulations

The reference products use lactose monohydrate. A lactose-free generic or differentiated product could target patients with lactose intolerance or buyers seeking broader excipient compatibility. Possible replacements include:

• Mannitol
• Isomalt
• Compressible sucrose
• Dibasic calcium phosphate
• Coprocessed cellulose systems
• Spray-dried polyols

Mannitol may improve mouthfeel but can affect compaction and moisture behavior. Dibasic calcium phosphate can improve tablet hardness but may introduce different dissolution and density characteristics. Any replacement must be evaluated against particle-size distribution, tablet tensile strength, disintegration, and bioequivalence.

Surfactant-reduced or surfactant-free systems

Sodium lauryl sulfate supports wetting but can produce taste and tolerability concerns. Potential alternatives include:

• Poloxamers
• Sodium dioctyl sulfosuccinate
• Lecithin
• Wet-milled drug particles
• Spray-dried amorphous dispersions
• Mesoporous silica or other particle-engineering systems

A surfactant-free formulation has commercial appeal, but it may require more advanced particle engineering. Deferasirox’s low solubility means that replacing sodium lauryl sulfate without a compensating dissolution technology could create a bioequivalence failure.

Orally disintegrating or rapidly dispersible tablets

An orally disintegrating tablet could reduce water requirements and improve use outside clinical settings. The main barriers are the relatively high deferasirox dose, the drug’s taste, and the need to maintain acceptable tablet size.

Potential approaches include:

• Highly porous lyophilized tablets
• Direct-compression orally disintegrating tablets
• Coated microparticles
• Sublingual or buccal taste-masked particles
• Effervescent dispersion systems

The high-dose nature of deferasirox makes a conventional orally disintegrating tablet less attractive than a granule or mini-tablet platform.

What patents protect oral deferasirox products?

The original deferasirox compound and product portfolio were protected through compound, formulation, and method-of-use rights. The foundational U.S. compound patent commonly associated with deferasirox is U.S. Patent No. 6,465,504, assigned to Novartis-related entities and directed to tridentate iron chelators including deferasirox.[3]

The main patent categories are:

Patent category	Commercial relevance
Compound patents	Protect deferasirox itself and related chelator structures
Pharmaceutical-composition patents	Cover dosage forms, excipient combinations, particle properties, or release behavior
Method-of-use patents	Cover treatment of transfusional iron overload and non-transfusion-dependent thalassemia
Salt, polymorph, or solid-state patents	May protect physical forms or improved stability
Manufacturing patents	May cover crystallization, particle-size control, milling, granulation, or coating
Pediatric or administration patents	May cover granules, sprinkle administration, or specific food vehicles

The practical significance of the patent estate depends on the exact claim scope, terminal disclaimers, patent-term adjustment, listed patents, and litigation history. FDA Orange Book entries, not the existence of a patent family alone, determine which listed patents can support an abbreviated new drug application challenge.[4]

When did core deferasirox exclusivity expire?

The foundational compound protection associated with U.S. Patent No. 6,465,504 reached the end of its ordinary term in the early 2020s, subject to patent-term adjustment and any applicable regulatory extensions.[3] Deferasirox therefore moved from a primarily branded market to a generic market in the United States.

The commercial risk has shifted from basic compound exclusion to:

• Product-specific formulation patents
• Method-of-use patents
• Pediatric exclusivity
• Orange Book listing strategy
• Paragraph IV litigation
• Manufacturing and supply-chain differentiation

What is the Orange Book status of deferasirox?

The Orange Book identifies approved reference products and patent information submitted by sponsors. Exjade and Jadenu are the relevant reference products for deferasirox oral dosage forms.[4]

For generic developers, Orange Book analysis should separate:

1. Tablets for oral suspension referencing Exjade.
2. Film-coated tablets referencing Jadenu.
3. Granules or sprinkle products referencing the applicable Jadenu presentation.
4. Patents listed against the specific NDA.
5. Patent claims that can be certified under Paragraph IV.
6. Method-of-use patents that may be carved out through a section viii statement.

A generic applicant does not need to reproduce every branded excipient. It must demonstrate pharmaceutical equivalence and bioequivalence under the applicable FDA requirements. A formulation that uses a different diluent, binder, lubricant, or surfactant can remain viable if it meets the relevant quality and bioequivalence standards.[5]

Which companies are challenging deferasirox exclusivity?

Deferasirox has been subject to generic competition because the active ingredient is a small molecule and the primary compound patent barrier has passed. FDA approval databases and commercial listings identify multiple generic suppliers across deferasirox tablet presentations, including products from major generic manufacturers and specialty suppliers.[6]

The most relevant competitive groups are:

• Large generic manufacturers with ANDA infrastructure
• Suppliers specializing in hematology products
• Companies with pediatric granule or sprinkle capabilities
• Contract manufacturers with high-potency solid-dose capacity
• Regional companies seeking regulated-market licenses

The competitive advantage is likely to come from reliable supply, low manufacturing cost, dosage-form breadth, and payer access rather than from a basic copy of the active ingredient.

What Paragraph IV risks exist for deferasirox?

Paragraph IV litigation risk is concentrated in later-listed formulation or method-of-use patents rather than the expired core compound patent. A generic applicant may challenge listed patents by asserting that they are invalid, not infringed, or not enforceable. The applicant may also use a section viii statement to omit a patented indication from its labeling.[4][5]

The primary Paragraph IV risk points are:

• Patents covering the Jadenu formulation
• Patents covering granule or sprinkle administration
• Patents covering dose conversion from Exjade to Jadenu
• Method-of-use claims directed to non-transfusion-dependent thalassemia
• Manufacturing claims tied to particle size or solid-state form

For commercial planning, a Paragraph IV filing can produce an earlier launch opportunity but also creates potential litigation expense and at-risk launch exposure. A non-infringing formulation with a different excipient system may reduce formulation-patent risk, but it does not eliminate method-of-use or manufacturing-patent exposure.

What generic launch scenarios exist for deferasirox?

Scenario 1: Low-cost Exjade-equivalent tablets

This is the lowest technical barrier. The product uses a conventional dispersible tablet and targets broad substitution. The main risks are dispersion time, sedimentation, taste, and patient adherence.

Scenario 2: Jadenu-equivalent film-coated tablets

This is commercially attractive because it addresses the administration burden of Exjade. The development program must establish bioequivalence to Jadenu and control dissolution across strengths.

Scenario 3: Pediatric granules

Granules can command a commercial premium if they improve administration for children. The product faces greater manufacturing, packaging, taste-masking, and dose-uniformity requirements.

Scenario 4: Differentiated lactose-free product

A lactose-free product can obtain institutional and specialty-pharmacy interest, particularly if it preserves Jadenu-like dosing and avoids a difficult administration process.

Scenario 5: Modified-release or high-solubility product

This is the highest-risk strategy. Deferasirox is used for chronic chelation, but a modified-release product may alter exposure, tolerability, and labeling. The product would likely require a more substantial clinical and regulatory program than a standard ANDA.

How strong is the deferasirox patent estate?

The estate is strongest against unauthorized use of the branded formulation or patented administration methods where valid, unexpired claims remain listed. It is weaker as a barrier to standard generic deferasirox products because the compound itself is no longer protected by its original long-term exclusivity.

Estate component	Relative strength for generic defense
Original compound patent	Low after expiration
Basic immediate-release oral formulation	Moderate to low, depending on claims
Jadenu-specific formulation claims	Potentially material
Granule and sprinkle claims	Potentially material for pediatric products
Method-of-use claims	Manageable through indication carve-outs in some cases
Manufacturing patents	Relevant if the generic uses the same process or solid form
Trade secrets and know-how	Material for branded manufacturing, but not automatically blocking

The strongest freedom-to-operate strategy is a differentiated formulation with independent excipient selection, distinct processing parameters, and a label that avoids unnecessary patented indications.

What licensing deals and partnership opportunities exist?

Publicly documented commercial opportunities are more likely to involve generic supply, regional commercialization, contract manufacturing, or specialty-pharmacy distribution than a new-originator license. The most valuable partnership targets are:

• Pediatric formulation developers
• Taste-masking technology companies
• High-potency tablet manufacturers
• Companies with iron-overload and thalassemia sales forces
• Regional pharmaceutical companies in markets with limited chelation access
• Suppliers with FDA-inspected granulation and coating facilities

A licensing transaction could be structured around a formulation platform rather than deferasirox itself. Potential deal assets include a lactose-free Jadenu-equivalent tablet, a taste-masked sprinkle product, or a manufacturing process that improves dissolution while reducing surfactant content.

What FDA regulatory pathway applies to new deferasirox oral products?

A conventional generic product would generally use the ANDA pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must demonstrate pharmaceutical equivalence and bioequivalence to the selected reference listed drug.[5]

A reformulated product with a clinically meaningful change in dosage form, route, release profile, or indication may require a 505(b)(2) application. The pathway depends on whether the product can rely on FDA findings for the reference product while submitting new data to support the change.

Product concept	Likely pathway
Same dosage form and strength as reference	ANDA
Different excipients with equivalent performance	ANDA, if pharmaceutical equivalence and bioequivalence are met
New granule or sprinkle presentation	ANDA or 505(b)(2), depending on reference and product characteristics
Modified-release formulation	Usually higher-risk 505(b)(2) strategy
New indication or dosing regimen	505(b)(2) or supplemental NDA
New pediatric administration technology	ANDA if equivalent; otherwise potentially 505(b)(2)

What commercial opportunities are most attractive?

The strongest opportunities are products that reduce adherence friction while remaining close enough to the reference product for an efficient regulatory program.

Opportunity	Commercial rationale	Main risk
Jadenu-equivalent generic tablets	Lower administration burden and established reference	Bioequivalence and formulation-patent exposure
Taste-masked pediatric granules	Addresses chronic pediatric adherence	Coating, taste, and dose-uniformity complexity
Lactose-free tablets or granules	Differentiates on excipient compatibility	Need to preserve dissolution and exposure
Low-surfactant formulation	May improve taste and tolerability	Reduced wetting and bioequivalence risk
Regional branded generic	Supports specialty pricing and distribution	Small patient population and reimbursement pressure
Contract manufacturing platform	Leverages existing solid-dose infrastructure	High-potency containment and validation

Revenue exposure is concentrated in chronic-use patients, particularly transfusion-dependent thalassemia, sickle-cell disease, myelodysplastic syndromes, and other transfusion-related iron-overload populations. The market is specialized, so unit volume is lower than for primary-care generics. Chronic dosing, specialist prescribing, and limited therapeutic alternatives can support better economics for differentiated products.

Key Takeaways

• Deferasirox oral competition is centered on Exjade dispersible tablets, Jadenu film-coated tablets, and Jadenu Sprinkle granules.
• The reference excipient platform relies on lactose, microcrystalline cellulose, crospovidone, povidone, sodium lauryl sulfate, colloidal silicon dioxide, and magnesium stearate.
• The main technical opportunity is to improve pediatric administration, taste, dispersion, and excipient compatibility.
• The original compound patent barrier has passed, but formulation, method-of-use, manufacturing, and granule-related patents may remain relevant.
• Generic applicants can use different excipients if they meet FDA pharmaceutical-equivalence, quality, labeling, and bioequivalence requirements.
• A Jadenu-equivalent tablet is the clearest commercial route; pediatric taste-masked granules offer higher differentiation but greater development risk.
• Deferasirox is a small molecule, so biosimilar risk does not apply. The relevant competitors are generic and specialty-generic manufacturers.
• The best licensing targets are formulation technologies, pediatric delivery systems, and manufacturing platforms rather than the active ingredient itself.

FAQs

Is deferasirox a biologic requiring biosimilar competition?

No. Deferasirox is a synthetic small-molecule iron chelator. Competition proceeds primarily through ANDAs and, for materially different products, 505(b)(2) applications.

Can a generic deferasirox product exclude lactose?

Yes. A generic may use a different diluent or excipient system if the product satisfies FDA quality, pharmaceutical-equivalence, bioequivalence, and labeling requirements.

Why is sodium lauryl sulfate important in deferasirox tablets?

Sodium lauryl sulfate improves wetting and can support dissolution of the poorly water-soluble active ingredient. Removing it may improve taste or tolerability but can create a dissolution and bioequivalence challenge.

Is a deferasirox granule product commercially superior to a tablet?

Granules may be superior for pediatric patients or patients unable to swallow tablets. They are more difficult to manufacture, package, taste-mask, and dose uniformly, so the commercial advantage depends on adherence improvement and payer acceptance.

Does a new deferasirox excipient combination avoid all patent risk?

No. A new excipient combination may reduce exposure to composition claims, but method-of-use, solid-state, manufacturing, and administration patents can remain relevant. FDA Orange Book listings and claim-by-claim freedom-to-operate analysis control the risk assessment.

References

1. U.S. Food and Drug Administration. (2023). Exjade (deferasirox) tablets for oral suspension prescribing information. Novartis Pharmaceuticals Corporation.

2. U.S. Food and Drug Administration. (2023). Jadenu (deferasirox) film-coated tablets and granules prescribing information. Novartis Pharmaceuticals Corporation.

3. United States Patent and Trademark Office. (2002). U.S. Patent No. 6,465,504: Iron chelating compounds. Novartis AG.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

5. U.S. Food and Drug Administration. (2024). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. FDA.

6. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. FDA.